SecBot SecBot
8-K ·Filed Nov 10, 2026

TYRA

Tyra Biosciences, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed6d 17h ago SEC0001193125-26-454474
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor upcoming regulatory engagement for Phase 3 adjuvant study design in IR NMIBC and initial BEACH301 safety sentinel cohort results, both expected in 2027. The $400M financing removes near-term dilution risk but increases share count.

DirectionNeutral
Confidencehigh
Horizonmonths

dabogratinib

◆ Mixed Named in this 8-K
Impact
Phase
Phase 2
Time to market
Dabogratinib is in Phase 2 development across all three indications. A pivotal Phase 3 study in NMIBC is being planned following the SURF302 data, but no specific start date has been given. The earliest potential approval would likely be several years away, contingent on successful Phase 3 data and FDA review.
Next catalyst
None dated

What to watchThe next hard catalyst is the BEACH301 Phase 2 safety sentinel cohort data in pediatric achondroplasia, expected by end of Q1 2027. Positive safety and growth data could re-rate the stock after the September 2026 SURF302 selloff; negative safety signals would damage the achondroplasia thesis. Separately, watch for details on a planned pivotal Phase 3 study in NMIBC, which would be the next major binary event for the bladder cancer program.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$21.00
T+0 close · Nov 10, 2026 · via day close
Latest settled
−0.14%
T+1 · $20.97
Vs SPY
−1.46%
α at T+1
Next horizon
T+5
in 6h
  1. T+0 · Nov 10 $21.00entry
  2. T+1 · 6d ago −0.14%α −1.46% · $20.97
  3. T+4 · todayOpen
  4. T+5 · in 6h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Tyra Biosciences reported Q3 2026 net loss of $51.1M, wider than the $29.9M loss in Q3 2025, driven by increased R&D spending on its dabogratinib clinical programs. The company highlighted initial Phase 2 SURF302 results showing a 79% ORR and 64% CR rate at 60 mg QD in IR NMIBC, and disclosed a $400M September financing that extended cash runway through 2030. No revenue or EPS consensus was provided for the current quarter.

Key Financial Metrics

EPS
−$0.74

Key Facts

  • Q3 2026 net loss of $51.1M vs $29.9M in Q3 2025
  • Cash, cash equivalents and marketable securities of $700.5M as of September 30, 2026
  • Completed $400M underwritten public offering in September 2026
  • Initial Phase 2 SURF302 results: 79% ORR and 64% CR rate at 60 mg QD in IR NMIBC
  • First SURF303 patient achieved CR at 3-month assessment with 60 mg QD
  • BEACH301 advanced to sixth dose level; initial results expected in 2027
  • R&D expenses $43.1M in Q3 2026 vs $25.5M in Q3 2025
  • Cash runway extended through 2030

Financial Impact

Net loss widened to $51.1M from $29.9M YoY; cash balance increased to $700.5M from $383.5M at Q1 2026 after $400M financing

net losscash positionR&D expenses

Risk Factors

  • Clinical-stage company with no approved products or revenue
  • Net loss widening as R&D spending increases across three Phase 2 trials
  • Initial SURF302 results are from a small sample (n=14) and may not predict final outcomes
  • Dependence on successful regulatory feedback for Phase 3 study design

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-454474
Document: tyra-20261110.htm0001193125-26-454474
Document: 0001193125-26-454474-index-headers.html0001193125-26-454474
Document: 0001193125-26-454474-index.html0001193125-26-454474
Document: 0001193125-26-454474.txt0001193125-26-454474
8-K Data (Synthetic)0001193125-26-454474

Track record

13 reports on TYRA

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +20.37% at T+60 after the Jun 26, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 10, 20266d ago 8-K Neutral 4/10 Viewing Entry $21.00 Now $19.74 −6.00% settles Nov 17
  2. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $21.75 to $21.53 Now $19.74 −9.24% ▼ −1.03% −0.32% vs SPY
  3. Sep 21, 20268w ago SC 13G Neutral 4/10 Entry $25.57 to $21.98 Now $19.74 −22.80% ▼ −14.04% −12.85% vs SPY
  4. Sep 17, 20268w ago Insider Cluster Bullish 8/10 Entry $25.73 to $21.76 Now $19.74 −23.28% ▼ −15.43% −16.70% vs SPY
  5. Sep 14, 20269w ago S-3ASR Neutral 3/10 Entry $25.07 to $25.65 Now $19.74 −21.26% ▲ +2.31% +2.21% vs SPY
  6. Sep 9, 20269w ago 8-K Bullish 6/10 Entry $22.01 to $24.35 Now $19.74 −10.31% ▲ +10.63% +11.73% vs SPY
  7. Aug 4, 202614w ago 424B5 Bearish 6/10 Entry $25.71 to $25.30 Now $19.74 +23.22% ▲ +1.59% +1.95% vs SPY
  8. Jun 26, 202620w ago 144 Bearish 6/10 Entry $32.11 to $30.86 Now $19.74 +38.52% ▲ +3.89% +5.28% vs SPY
  9. May 13, 202626w ago 8-K Mixed 5/10 Entry $36.19 to $33.78 Now $19.74 −45.45% ▼ −6.66% −5.50% vs SPY
  10. Apr 20, 202630w ago 3 Neutral 2/10 Entry $36.69 to $35.06 Now $19.74 −46.20% ▼ −4.44% −5.53% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 8h 16m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026